Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.

Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H.

Medicine (Baltimore). 2019 Aug;98(33):e16771. doi: 10.1097/MD.0000000000016771.

2.

Chimeric antigen receptor T cell therapy for multiple myeloma.

Hasegawa K, Hosen N.

Inflamm Regen. 2019 Jun 4;39:10. doi: 10.1186/s41232-019-0100-6. eCollection 2019. Review.

3.

Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.

Kinehara Y, Nagatomo I, Koyama S, Ito D, Nojima S, Kurebayashi R, Nakanishi Y, Suga Y, Nishijima-Futami Y, Osa A, Nakatani T, Kato Y, Nishide M, Hayama Y, Higashiguchi M, Morimura O, Miyake K, Kang S, Minami T, Hirata H, Iwahori K, Takimoto T, Takamatsu H, Takeda Y, Hosen N, Hoshino S, Shintani Y, Okumura M, Kumagai T, Nishino K, Imamura F, Nakatsuka SI, Kijima T, Kida H, Kumanogoh A.

JCI Insight. 2018 Dec 20;3(24). pii: 123093. doi: 10.1172/jci.insight.123093.

4.

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.

Nakata J, Nakajima H, Hayashibara H, Imafuku K, Morimoto S, Fujiki F, Motooka D, Okuzaki D, Hasegawa K, Hosen N, Tsuboi A, Oka Y, Kumanogoh A, Oji Y, Sugiyama H.

Oncotarget. 2018 Nov 13;9(89):36029-36038. doi: 10.18632/oncotarget.26338. eCollection 2018 Nov 13.

5.

A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H.

Cancer Immunol Immunother. 2019 Feb;68(2):331-340. doi: 10.1007/s00262-018-2274-1. Epub 2018 Nov 14.

6.

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity.

Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, Aoyama N, Nishida Y, Tsuboi A, Oka Y, Nishida S, Nakata J, Hosen N, Oji Y, Sugiyama H.

Oncotarget. 2018 Sep 25;9(75):34132-34141. doi: 10.18632/oncotarget.26139. eCollection 2018 Sep 25.

7.

[Chimeric antigen receptor T-cell therapy for multiple myeloma].

Hosen N.

Rinsho Ketsueki. 2018;59(10):2189-2194. doi: 10.11406/rinketsu.59.2189. Review. Japanese.

PMID:
30305525
8.

WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.

Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H.

Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21.

9.

The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A.

Nat Med. 2017 Dec;23(12):1436-1443. doi: 10.1038/nm.4431. Epub 2017 Nov 6.

PMID:
29106400
10.

Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.

Oka Y, Tsuboi A, Nakata J, Nishida S, Hosen N, Kumanogoh A, Oji Y, Sugiyama H.

Oncol Res Treat. 2017;40(11):682-690. doi: 10.1159/000481353. Epub 2017 Oct 18. Review.

11.

Wilms tumour 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse.

Nakata J, Nakae Y, Kawakami M, Morimoto S, Motooka D, Hosen N, Fujiki F, Nakajima H, Hasegawa K, Nishida S, Tsuboi A, Oji Y, Oka Y, Kumanogoh A, Sugiyama H.

Br J Haematol. 2018 Jul;182(2):287-290. doi: 10.1111/bjh.14768. Epub 2017 May 23. No abstract available.

PMID:
28542830
12.

Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.

Takashima S, Oka Y, Fujiki F, Morimoto S, Nakajima H, Nakae Y, Nakata J, Nishida S, Hosen N, Tatsumi N, Mizuguchi K, Hashimoto N, Oji Y, Tsuboi A, Kumanogoh A, Sugiyama H.

Future Sci OA. 2016 Oct 3;2(4):FSO96. doi: 10.4155/fsoa-2015-0008. eCollection 2016 Dec.

13.

Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.

Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Oji Y, Oka Y, Sugiyama H.

Stem Cell Investig. 2016 Dec 9;3:90. doi: 10.21037/sci.2016.11.08. eCollection 2016. Review.

14.

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.

Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, Chiba Y, Izumoto S, Elisseeva O, Ichinohasama R, Sakamoto J, Morita S, Nakajima H, Takashima S, Nakae Y, Nakata J, Kawakami M, Nishida S, Hosen N, Fujiki F, Morimoto S, Adachi M, Iwamoto M, Oka Y, Yoshimine T, Sugiyama H.

Int J Cancer. 2016 Sep 15;139(6):1391-401. doi: 10.1002/ijc.30182. Epub 2016 May 31.

15.

Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis.

Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakano K, Kinoshita H, Okumura A, Fujioka Y, Urakawa R, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Miyoshi E, Hirata T, Kumanogoh A, Sugiyama H, Hosen N.

PLoS One. 2016 Mar 24;11(3):e0152326. doi: 10.1371/journal.pone.0152326. eCollection 2016.

16.

An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.

Kondo K, Fujiki F, Nakajima H, Yatsukawa E, Morimoto S, Tatsumi N, Nishida S, Nakata J, Oka Y, Tsuboi A, Hosen N, Oji Y, Sugiyama H.

J Immunother. 2016 Apr;39(3):127-39. doi: 10.1097/CJI.0000000000000114.

PMID:
26938946
17.

A Zbtb7a proto-oncogene as a novel target for miR-125a.

Hojo N, Tatsumi N, Moriguchi N, Matsumura A, Morimoto S, Nakata J, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Hayashi S, Sugiyama H, Oji Y.

Mol Carcinog. 2016 Dec;55(12):2001-2009. doi: 10.1002/mc.22446. Epub 2015 Dec 29.

PMID:
26713860
18.

An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells.

Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakajima H, Tatsumi N, Nakata J, Takashima S, Nishida S, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Hosen N.

PLoS One. 2015 Dec 11;10(12):e0144594. doi: 10.1371/journal.pone.0144594. eCollection 2015.

19.

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms.

Tatsumi N, Hojo N, Sakamoto H, Inaba R, Moriguchi N, Matsuno K, Fukuda M, Matsumura A, Hayashi S, Morimoto S, Nakata J, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Sugiyama H, Oji Y.

PLoS One. 2015 Jun 19;10(6):e0130578. doi: 10.1371/journal.pone.0130578. eCollection 2015.

20.

[Identification and targeting of multiple myeloma stem cells].

Hosen N.

Nihon Rinsho. 2015 May;73(5):816-22. Japanese.

PMID:
25985637
21.

Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Tatsumi N, Hojo N, Yamada O, Ogawa M, Katsura Y, Kawata S, Morii E, Sakamoto H, Inaba R, Tsuda A, Fukuda I, Moriguchi N, Hasuwa H, Okabe M, Fujiki F, Nishida S, Nakajima H, Tsuboi A, Oka Y, Hosen N, Sugiyama H, Oji Y.

Oncogene. 2016 Feb 25;35(8):1003-14. doi: 10.1038/onc.2015.154. Epub 2015 May 11.

PMID:
25961914
22.

Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension.

Hashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, Masaki T, Minami M, Inagaki T, Miyagawa S, Sawa Y, Murakami M, Kumanogoh A, Yamauchi-Takihara K, Okumura M, Kishimoto T, Komuro I, Shirai M, Sakata Y, Nakaoka Y.

Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2677-86. doi: 10.1073/pnas.1424774112. Epub 2015 May 4.

23.

Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.

Nakae Y, Oka Y, Fujiki F, Morimoto S, Kamiya T, Takashima S, Nakata J, Nishida S, Nakajima H, Hosen N, Tsuboi A, Kyo T, Oji Y, Mizuguchi K, Kumanogoh A, Sugiyama H.

Cancer Immunol Immunother. 2015 Jul;64(7):791-804. doi: 10.1007/s00262-015-1683-7. Epub 2015 Apr 3.

PMID:
25835542
24.

Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.

Hashimoto N, Tsuboi A, Kagawa N, Chiba Y, Izumoto S, Kinoshita M, Kijima N, Oka Y, Morimoto S, Nakajima H, Morita S, Sakamoto J, Nishida S, Hosen N, Oji Y, Arita N, Yoshimine T, Sugiyama H.

Cancer Immunol Immunother. 2015 Jun;64(6):707-16. doi: 10.1007/s00262-015-1674-8. Epub 2015 Mar 14.

PMID:
25772149
25.

Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.

Katsuhara A, Fujiki F, Aoyama N, Tanii S, Morimoto S, Oka Y, Tsuboi A, Nakajima H, Kondo K, Tatsumi N, Nakata J, Nakae Y, Takashima S, Nishida S, Hosen N, Sogo S, Oji Y, Sugiyama H.

Anticancer Res. 2015 Mar;35(3):1251-61.

PMID:
25750272
26.

[Multiple myeloma stem cell].

Hosen N.

Nihon Rinsho. 2015 Jan;73(1):47-51. Japanese.

PMID:
25626303
27.

The Wilms' tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression.

Wagner KD, Cherfils-Vicini J, Hosen N, Hohenstein P, Gilson E, Hastie ND, Michiels JF, Wagner N.

Nat Commun. 2014 Dec 16;5:5852. doi: 10.1038/ncomms6852.

PMID:
25510679
28.

Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair.

Oji Y, Tatsumi N, Kobayashi J, Fukuda M, Ueda T, Nakano E, Saito C, Shibata S, Sumikawa M, Fukushima H, Saito A, Hojo N, Suzuki M, Hoshikawa T, Shimura T, Morii E, Oka Y, Hosen N, Komatsu K, Sugiyama H.

Mol Carcinog. 2015 Dec;54(12):1758-71. doi: 10.1002/mc.22248. Epub 2014 Nov 21.

PMID:
25418835
29.

Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.

Hosen N, Maeda T, Hashii Y, Tsuboi A, Nishida S, Nakata J, Nakae Y, Takashima S, Oji Y, Oka Y, Kumanogoh A, Sugiyama H.

Expert Rev Hematol. 2014 Oct;7(5):671-81. doi: 10.1586/17474086.2014.953925. Epub 2014 Sep 4. Review.

PMID:
25186852
30.

The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.

Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S, Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T, Shimizu Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S, Nonomura N, Yoshimine T, Okumura M, Morii E, Maeda H, Nishida S, Hosen N, Tsuboi A, Oka Y, Sugiyama H.

Int J Oncol. 2014 May;44(5):1461-9. doi: 10.3892/ijo.2014.2318. Epub 2014 Mar 4.

31.

Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.

Shima Y, Hosen N, Hirano T, Arimitsu J, Nishida S, Hagihara K, Narazaki M, Ogata A, Tanaka T, Kishimoto T, Kumanogoh A.

Mod Rheumatol. 2015 Jan;25(1):134-7. doi: 10.3109/14397595.2013.874749. Epub 2014 Feb 18.

PMID:
24533556
32.

Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.

Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Kitagawa T, Eguchi H, Wada H, Nagano H, Nakata J, Nakae Y, Hosen N, Oji Y, Tanaka T, Kawase I, Kumanogoh A, Sakamoto J, Doki Y, Mori M, Ohkusa T, Tajiri H, Sugiyama H.

J Immunother. 2014 Feb-Mar;37(2):105-14. doi: 10.1097/CJI.0000000000000020.

33.

Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis.

Kijima N, Hosen N, Kagawa N, Hashimoto N, Kinoshita M, Oji Y, Sugiyama H, Yoshimine T.

Anticancer Res. 2014 Jan;34(1):61-7.

PMID:
24403445
34.

In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity.

Nakata J, Nakano K, Okumura A, Mizutani Y, Kinoshita H, Iwai M, Hasegawa K, Morimoto S, Fujiki F, Tatsumi N, Nakajima H, Nakae Y, Nishida S, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Kumanogoh A, Hosen N.

Leukemia. 2014 Jun;28(6):1316-25. doi: 10.1038/leu.2013.374. Epub 2013 Nov 13.

PMID:
24336127
35.

Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine.

Maeda T, Hosen N, Fukushima K, Tsuboi A, Morimoto S, Matsui T, Sata H, Fujita J, Hasegawa K, Nishida S, Nakata J, Nakae Y, Takashima S, Nakajima H, Fujiki F, Tatsumi N, Kondo T, Hino M, Oji Y, Oka Y, Kanakura Y, Kumanogoh A, Sugiyama H.

Blood Cancer J. 2013 Aug 2;3:e130. doi: 10.1038/bcj.2013.29. No abstract available.

36.

[Identification of myeloma-initiating cells and development of their targeting therapy].

Hosen N, Sugiyama H.

Rinsho Ketsueki. 2013 Jun;54(6):505-12. Review. Japanese. No abstract available.

PMID:
23823088
37.

HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.

Lin Y, Fujiki F, Katsuhara A, Oka Y, Tsuboi A, Aoyama N, Tanii S, Nakajima H, Tatsumi N, Morimoto S, Tamanaka T, Tachino S, Hosen N, Nishida S, Oji Y, Kumanogoh A, Sugiyama H.

J Immunother. 2013 Apr;36(3):159-70. doi: 10.1097/CJI.0b013e3182873581.

PMID:
23502763
38.

Multiple myeloma-initiating cells.

Hosen N.

Int J Hematol. 2013 Mar;97(3):306-12. doi: 10.1007/s12185-013-1293-0. Epub 2013 Feb 19. Review.

PMID:
23420183
39.

Functional human Th17 clones with WT1-specific helper activity.

Tachino S, Fujiki F, Oka Y, Tsuboi A, Morimoto S, Lin YH, Tamanaka T, Kondo K, Nakajima H, Nishida S, Hosen N, Oji Y, Kumanogoh A, Sugiyama H.

Cancer Immunol Immunother. 2013 Apr;62(4):801-10. doi: 10.1007/s00262-012-1385-3. Epub 2012 Dec 29.

PMID:
23275045
40.

Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.

Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, Hosen N, Nishida S, Lin YH, Tachino S, Akatsuka Y, Kuzushima K, Oji Y, Kumanogoh A, Sugiyama H.

Anticancer Res. 2012 Dec;32(12):5201-9.

PMID:
23225417
41.

WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.

Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, Nakatsuka S, Morita S, Sakamoto J, Sugiyama H, Kimura T.

J Cancer Res Clin Oncol. 2013 Mar;139(3):457-63. doi: 10.1007/s00432-012-1348-2. Epub 2012 Nov 18.

PMID:
23160854
42.

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.

Hosen N, Matsuoka Y, Kishida S, Nakata J, Mizutani Y, Hasegawa K, Mugitani A, Ichihara H, Aoyama Y, Nishida S, Tsuboi A, Fujiki F, Tatsumi N, Nakajima H, Hino M, Kimura T, Yata K, Abe M, Oka Y, Oji Y, Kumanogoh A, Sugiyama H.

Leukemia. 2012 Sep;26(9):2135-41. doi: 10.1038/leu.2012.80. Epub 2012 Mar 20.

PMID:
22430638
43.

WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.

Shirakata T, Oka Y, Nishida S, Hosen N, Tsuboi A, Oji Y, Murao A, Tanaka H, Nakatsuka S, Inohara H, Sugiyama H.

Anticancer Res. 2012 Mar;32(3):1081-5.

PMID:
22399636
44.

CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion.

Kijima N, Hosen N, Kagawa N, Hashimoto N, Nakano A, Fujimoto Y, Kinoshita M, Sugiyama H, Yoshimine T.

Neuro Oncol. 2012 Oct;14(10):1254-64. Epub 2011 Dec 13.

45.

Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease.

Tsuboi A, Oka Y, Kyo T, Katayama Y, Elisseeva OA, Kawakami M, Nishida S, Morimoto S, Murao A, Nakajima H, Hosen N, Oji Y, Sugiyama H.

Leukemia. 2012 Jun;26(6):1410-3. doi: 10.1038/leu.2011.343. Epub 2011 Dec 13. No abstract available.

PMID:
22157809
46.

Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.

Nakajima H, Oka Y, Tsuboi A, Tatsumi N, Yamamoto Y, Fujiki F, Li Z, Murao A, Morimoto S, Hosen N, Shirakata T, Nishida S, Kawase I, Isaka Y, Oji Y, Sugiyama H.

Vaccine. 2012 Jan 17;30(4):722-9. doi: 10.1016/j.vaccine.2011.11.074. Epub 2011 Nov 29.

PMID:
22133512
47.

Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.

Morimoto S, Oka Y, Tsuboi A, Tanaka Y, Fujiki F, Nakajima H, Hosen N, Nishida S, Nakata J, Nakae Y, Maruno M, Myoui A, Enomoto T, Izumoto S, Sekimoto M, Kagawa N, Hashimoto N, Yoshimine T, Oji Y, Kumanogoh A, Sugiyama H.

Cancer Sci. 2012 Mar;103(3):408-14. doi: 10.1111/j.1349-7006.2011.02163.x. Epub 2012 Jan 17.

48.

CD48 as a novel molecular target for antibody therapy in multiple myeloma.

Hosen N, Ichihara H, Mugitani A, Aoyama Y, Fukuda Y, Kishida S, Matsuoka Y, Nakajima H, Kawakami M, Yamagami T, Fuji S, Tamaki H, Nakao T, Nishida S, Tsuboi A, Iida S, Hino M, Oka Y, Oji Y, Sugiyama H.

Br J Haematol. 2012 Jan;156(2):213-24. doi: 10.1111/j.1365-2141.2011.08941.x. Epub 2011 Nov 21.

PMID:
22098460
49.

WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission.

Hashii Y, Sato-Miyashita E, Matsumura R, Kusuki S, Yoshida H, Ohta H, Hosen N, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Ozono K.

Leukemia. 2012 Mar;26(3):530-2. doi: 10.1038/leu.2011.226. Epub 2011 Aug 26. No abstract available.

PMID:
21869838
50.

[WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].

Oka Y, Tsuboi A, Nishida S, Hosen N, Nakata J, Hashii Y, Maeda T, Oji Y, Kumanogoh A, Sugiyama H.

Rinsho Ketsueki. 2011 May;52(5):235-42. Review. Japanese. No abstract available.

PMID:
21646768

Supplemental Content

Support Center